Log in

NYSEAMERICAN:NBY - NovaBay Pharmaceuticals Stock Price, Forecast & News

$0.58
0.00 (0.00 %)
(As of 12/8/2019 04:00 PM ET)
Today's Range
$0.58
Now: $0.58
$0.60
50-Day Range
$0.45
MA: $0.68
$1.20
52-Week Range
$0.23
Now: $0.58
$4.04
Volume149,187 shs
Average Volume1.13 million shs
Market Capitalization$16.32 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:NBY
CUSIPN/A
Phone+1-510-8998800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees70
Market Cap$16.32 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive NBY News and Ratings via Email

Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.


NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

Shares of NovaBay Pharmaceuticals reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.09. The biopharmaceutical company had revenue of $4.09 million for the quarter, compared to the consensus estimate of $4.69 million. View NovaBay Pharmaceuticals' Earnings History.

When is NovaBay Pharmaceuticals' next earnings date?

NovaBay Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for NovaBay Pharmaceuticals.

What guidance has NovaBay Pharmaceuticals issued on next quarter's earnings?

NovaBay Pharmaceuticals issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$6-8 million, compared to the consensus revenue estimate of $$7.65 million.

What price target have analysts set for NBY?

3 equities research analysts have issued twelve-month target prices for NovaBay Pharmaceuticals' shares. Their forecasts range from $1.10 to $2.00. On average, they expect NovaBay Pharmaceuticals' share price to reach $1.55 in the next year. This suggests a possible upside of 165.0% from the stock's current price. View Analyst Price Targets for NovaBay Pharmaceuticals.

What is the consensus analysts' recommendation for NovaBay Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NovaBay Pharmaceuticals.

Has NovaBay Pharmaceuticals been receiving favorable news coverage?

News coverage about NBY stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NovaBay Pharmaceuticals earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for NovaBay Pharmaceuticals.

Are investors shorting NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals saw a drop in short interest in the month of November. As of November 15th, there was short interest totalling 230,800 shares, a drop of 28.5% from the October 31st total of 322,800 shares. Based on an average daily trading volume, of 888,300 shares, the days-to-cover ratio is presently 0.3 days. Currently, 1.5% of the company's shares are sold short. View NovaBay Pharmaceuticals' Current Options Chain.

Who are some of NovaBay Pharmaceuticals' key competitors?

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the folowing people:
  • Mr. Justin M. Hall, Interim Pres, CEO, Gen. Counsel & Corp. Sec. (Age 41)
  • Mr. Jason Philip Raleigh, Interim CFO, Treasurer & Corp. Controller (Age 42)
  • Dr. David W. Stroman, Sr. VP of Ophthalmic Product Devel. & Chair of Ophthalmology Advisory Board (Age 74)

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $0.58.

How big of a company is NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals has a market capitalization of $16.32 million. NovaBay Pharmaceuticals employs 70 workers across the globe.View Additional Information About NovaBay Pharmaceuticals.

What is NovaBay Pharmaceuticals' official website?

The official website for NovaBay Pharmaceuticals is http://novabay.com/.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.


MarketBeat Community Rating for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  201 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  375
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe NBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel